Brief: Arrowhead Pharmaceuticals Q3 EPS USD -1.36
04/08/2026 21:02
BRIEF-Arrowhead Pharmaceuticals Q3 EPS USD -1.36 Aug 04 (Reuters) - Arrowhead Pharmaceuticals Q3 operating expenses USD 245.346 million.
- Q3 revenue USD 75.253 million vs. IBES estimate USD 54.3 million
- Q3 operating income USD -170.093 million
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers